Literature DB >> 23728385

Erythropoietin prevents lymphoid apoptosis but has no effect on survival in experimental sepsis.

Tolga F Köroğlu1, Osman Yılmaz, Necati Gökmen, Kazım Tuğyan, Hüseyin Baskın, Mehtap Yüksel Eğrilmez.   

Abstract

BACKGROUND: Lymphoid apoptosis in sepsis is associated with poor outcome, and prevention of apoptosis frequently improves survival in experimental models of sepsis. Recently, erythropoietin (EPO) was shown to protect against lipopolysaccharide (LPS)-induced mortality. As cecal ligation and puncture (CLP) is a clinically more relevant model of sepsis, we evaluated the effect of EPO on CLP-induced lymphoid tissue apoptosis and mortality.
METHODS: Young Wistar rats were subjected to polymicrobial sepsis by CLP. EPO (5,000 U/kg intraperitoneal) was administered 30 min before CLP and then 1 and 4 h after CLP. Spleen, thymus, and small intestine were harvested at 24 h and assessed for apoptosis by terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) and caspase-3 staining. A separate group of animals was followed up for mortality.
RESULTS: Splenic, thymic, and intestinal apoptosis was increased after CLP; administration of EPO significantly decreased apoptosis as determined by TUNEL and caspase-3 staining. Final survival in the CLP mortality study was 30% in both saline and EPO groups.
CONCLUSION: Our results provide the first evidence that EPO attenuates lymphoid apoptosis in the CLP model of sepsis. However, EPO is not associated with a survival benefit in the CLP model of sepsis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728385     DOI: 10.1038/pr.2013.86

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  5 in total

1.  Inhibition of Toll-like receptor 9 attenuates sepsis-induced mortality through suppressing excessive inflammatory response.

Authors:  Dan Hu; Xiaohua Yang; Yanxiao Xiang; Hui Li; Hui Yan; Jun Zhou; Yi Caudle; Xiumei Zhang; Deling Yin
Journal:  Cell Immunol       Date:  2015-03-31       Impact factor: 4.868

2.  Systemic Lipopolysaccharide Administration-Induced Cognitive Impairments are Reversed by Erythropoietin Treatment in Mice.

Authors:  Rong Gao; Yuan-hui Tang; Jian-hua Tong; Jian-Jun Yang; Mu-huo Ji; Si-hai Zhu
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

3.  Erythropoietin Pretreatment Attenuates Seawater Aspiration-Induced Acute Lung Injury in Rats.

Authors:  Mu-Huo Ji; Jian-Hua Tong; Yuan-Hui Tan; Zhen-Yu Cao; Cong-Yang Ou; Wei-Yan Li; Jian-Jun Yang; Y G Peng; Si-Hai Zhu
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

Review 4.  Is There a Role for Hematopoietic Growth Factors During Sepsis?

Authors:  Benjamin G Chousterman; Marine Arnaud
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

5.  Repurposing of High-Dose Erythropoietin as a Potential Drug Attenuates Sepsis in Preconditioning Renal Injury.

Authors:  Wiwat Chancharoenthana; Kanyarat Udompronpitak; Yolradee Manochantr; Piyawat Kantagowit; Ponthakorn Kaewkanha; Jiraporn Issara-Amphorn; Asada Leelahavanichkul
Journal:  Cells       Date:  2021-11-12       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.